Sygnis
Expedeon to Sell Proteomics, Immunology Businesses to Abcam for $130M
The deal includes Expedeon's core proteomics business, as well as its immunology-focused subsidiaries Innova Biosciences and TGR Biosciences.
Expedeon Posts 18 Percent Q2 Revenue Increase
The revenue growth was driven in part by sales generated by Australian reagent maker TGR Biosciences, which Expedeon acquired in May last year.
Expedeon Posts 68 Percent Rise in 2018 Revenues
The German research products firm attributed the higher revenues to organic growth, as well as the impact of recent acquisitions such as TGR Biosciences.
Expedeon Secures £5M in Debt Financing
The firm will use the agreement to access alternative non-dilutive means of financing of its growth plans.
Expedeon Posts 106 Percent Jump in Q2 Revenues
The company, which has just changed its name from Sygnis, has now completed the integration of several recent acquisitions including TGR Biosciences.
May 11, 2018
Sygnis Posts 64 Percent Q1 Revenue Increase
May 8, 2018
Sygnis Closes TGR Biosciences Acquisition
Mar 20, 2018